Introduction
Wilson's disease is a disorder of biliary copper excretion due of Northern and Eastern European ancestry is the H1069Q mutation, with a frequency ranging from 36% in Sweden to to mutations in the ATP7B gene located on chromosome 13 (Petrukhin et al., 1994) . The prevalence of Wilson's disease 93% in Poland (Thomas et al., 1995; Czlonkowska et al., 1997; Gollan and Gollan, 1998) . In Austria, the H1069Q is~1 in 30 000 live births (Gollan and Gollan, 1998) . Patients homozygous for the H1069Q mutation present more mutation is present in 61% of Wilson disease patients (21% homozygous, 40% compound heterozygous). frequently with neurological than hepatic symptoms compared with patients heterozygous for H1069Q, or patients
The wide spectrum of symptoms and the difference in age at onset of clinical manifestations in Wilson's disease raise with other or unknown mutations (Maier-Dobersberger et al., 1997) . Various defects of the ATP7B gene product, a copperthe question of whether these features are determined exclusively by the type of the ATP7B mutation or by other transporting P-type ATPase, cause an accumulation of copper in the liver and other organs, such as kidneys, cornea and genetic factors, such as apolipoprotein E (ApoE) genotypes. There is evidence that ApoE genotypes containing the ε4 brain. The most common mutation in Wilson disease patients allele are over-represented in patients with rapidly progressing Kayser-Fleischer rings around the iris. In 43% of our patients, an MRI examination of the brain was performed, and in dementia in Alzheimer's disease (Welsh-Bohmer et al., 1997) . In a similar vein, several working groups have reported a 45% of the patients somatosensory evoked potentials were measured (Grimm et al., 1990) . less favourable neuropsychiatric outcome after traumatic, epileptic or haemorrhagic brain injury in patients with the Each patient was examined by two experienced, independent neurologists. Neuropsychiatric symptoms, such ApoE ε4 allele compared with patients with other ApoE alleles (Alberts et al., 1995; Gouras et al., 1997; Teasdale as tremor, dysarthria, ataxia, rigidity, dyskinesia, cognitive impairment and mood disturbances, were assessed in a et al ., 1997) . The mechanisms by which the ApoE 3 protein attenuates neuronal vulnerability in vivo are unknown.
semiquantitave fashion and ranged from 0 (completely normal) to 3 (severely impaired). Patients without major However, in vitro investigations have shown that ApoE 3 stimulates the branching of growing neurons and prevents hepatic symptoms and with scores ജ 2 for one or more neurological symptoms at the time of diagnosis, at any time neuronal death in conditions of oxidative stress (Nathan et al., 1994; Miyata and Smith, 1996) Wilson's disease, 60 patients presented with neurological ApoE genotypes and the H1069Q mutation in the group of symptoms, 61 patients with hepatic symptoms, and 88 patients 34 patients excluded were not different from those of the exhibited the H1069Q mutation (41 homozygous, 47 group of 121 patients whose data were used for statistical compound heterozygous). Patients homozygous for the analysis.
H1069Q mutation were classified more often as neurological Wilson's disease was diagnosed on the basis of typical than compound heterozygous and H1069Q-negative patients symptoms and the presence of conventional biochemical (Table 1) . Our 61 hepatic patients were younger at the onset indicators (plasma ceruloplasmin Ͻ200 mg/l, serum copper of symptoms than our 60 neurological patients (19 Ϯ 7 Ͻ10 µmol/l, 24 h urine copper excretion ജ2 µmol/day and/ versus 23 Ϯ 7 years; t ϭ 3.39, P ϭ 0.001). No genderor liver copper concentrations Ͼ250 mg/g on needle biopsy). All patients were examined by slit-lamp for the presence of specific differences were found with respect to clinical Table 1 (ApoE ε3/3 ϭ 59%, ε3/4 ϭ 21%, ε3/2 ϭ 19%). One textbooks and are thus missed (Steindl et al., 1997) . In this study, most patients were recruited in a single centre where H1069Q-homozygous, neurological patient exhibiting the genotype ApoE ε4/2 was excluded from statistical analysis they underwent a standardized neurological and hepatological evaluation. The 78 Austrian index patients in this study with respect to ApoE genotypes for uniqueness. None of our patients had the extremely rare allele combinations ApoE represent 90% of all known Wilson disease families in this country. The second largest group of patients enrolled in this ε4/4 or ε2/2. The overall ApoE genotype distribution in our patients was similar to that in healthy European subjects (de study was diagnosed at the University of Leipzig, a known referral centre for Wilson's disease, according to the same Knijff et al., 1994; Siest et al., 1995; Schmidt et al., 1997) and was homogenous within the two subgroups classified principles as in the Austrian centre. In addition, definition of disease onset is quite difficult. Early diagnosis is missed in according to the H1069Q mutation status and clinical symptoms at presentation (Table 1) . a substantial proportion of patients because of neurological or hepatic symptoms unrelated to Wilson's disease. In some Since the age of onset of symptoms and phenotypic disease expression depend on the type of defect of the Wilson disease patients, birth trauma or head injury result in neurological symptoms similar to those in Wilson's disease. Likewise, gene (Thomas et al., 1995; Maier-Dobersberger et al., 1997; Shah et al., 1997; Gollan and Gollan, 1998) , we established severe alcohol abuse may mimic neurological and hepatic symptoms otherwise characteristic of Wilson's disease. In three subgroups (H1069Q-homozygous, H1069Q-heterozygous and H1069Q-negative) for further statistical analysis. some primarily hepatic cases, Wilson's disease is diagnosed only after the onset of Wilson disease-specific neurological Other unknown mutations in H1069Q-heterozygous and H1069Q-negative patients influence phenotypic disease symptoms. Finally, there are Ͼ50 known mutations of the Wilson disease gene, most of which are rare and occur in expression and may abolish the positive effect of the ApoE ε3/3 genotype with respect to a delayed onset of symptoms. single patients only. Moreover, a large proportion of Wilson disease patients have two different mutations (compound This was indeed the case in our patients, where disease onset was early irrespective of the ApoE genotypes present (47 heterozygotes). Some mutations are associated with severe dysfunctions of the Wilson disease gene product and H1069Q-heterozygous patients: 20 Ϯ 9 years; 33 H1069Q-negative patients: 20 Ϯ 8 years).
frequently cause serious liver disease in early childhood; other mutations are less severe and are associated with lateThe genetic defect is well characterized in H1069Q-homozygous patients, therefore the investigation of additional onset neurological disease. Of the known mutations, only a few occur in a larger number of families. Sufficient clinical genetic factors is easier. By stratifying all patients who were homozygous for the H1069Q mutation (n ϭ 40) into three information is available only for the H1069Q mutation. This mutation occurs in 30-90% of patients of Northern European ApoE groups (ApoE ε3/3, ApoE ε3/4 and ApoE ε3/2) and two groups according to clinical symptoms (neurological or (Waldenstrom et al., 1996) , Central European (MaierDobersberger et al., 1997) and Eastern European hepatic), we found that neurological patients were older at presentation than hepatic patients and that the age at onset (Czlonkowska et al., 1997) origin. Most patients who are homozygous for the H1069Q mutation present with of symptoms is determined by the ApoE genotype (Fig. 1) . No interaction between the clinical symptoms and the ApoE neurological symptoms with a late onset (Houwen et al., 1995; Maier-Dobersberger et al., 1997) . The H1069Q mutation is genotypes was found and neither was synergistic. Post hoc comparison showed that H1069Q-homozygous patients with regarded as a 'mild' mutation which does not completely disrupt biliary copper transport and thus delays the the ApoE ε3/3 genotype were significantly older at onset of manifestation of symptoms (Thomas et al., 1995;  synthesis) are decreased in several hepatic disorders, such as hepatitis and toxin-induced liver failure, whereas regenerating Czlonkowska et al., 1997). Our results are in agreement with previous findings on H1069Q homozygosity and late-onset liver tissue requires a high cholesterol supply (Fukushima et al., 1993) . Different ApoE isoforms have different affinities neurological Wilson's disease (Petrukhin et al., 1994; Houwen et al., 1995; Czlonkowska et al., 1997; Maier-Dobersberger for the LDL receptor. ApoE 2 shows a defective binding activity leading to an upregulation of the LDL receptor, et al., 1997). However, this genotype-phenotype correlation was not found in a study on 109 North American and thereby inducing hypocholesterinaemia, whereas ApoE 4 induces a downregulation of the LDL receptor leading to Canadian patients (30 of whom were H1069Q-homozygous) mainly because of selection bias and the availability of hypercholesterinaemia (Siest et al., 1995) . Furthermore, the plasma concentrations of ApoE itself, of other apolipoproteins clinical data in only~60% of the patients (Shah et al., 1997) . Larger population-based studies should address the question and of triglycerides vary within individuals with different ApoE allelic combinations (Siest et al., 1995) . of whether additional genetic factors influence the age at onset of symptoms and phenotypic disease expression in Several biochemical mechanisms may explain why the onset of neurological as well as hepatic symptoms occurs Wilson's disease.
The influence of ApoE genotypes on disease onset and the later in Wilson disease patients with the ApoE ε3/3 genotype compared with patients with other ApoE genotypes. The severity of symptoms has been investigated mainly in several neuropsychiatric disorders and in patients with impaired cytotoxic effect of copper is mediated by the production of highly reactive radicals that might damage cell membranes lipoprotein lipid metabolism. ApoE 4 has been identified as a risk factor in Alzheimer's disease and worsens neurological by lipid peroxidation. It is not clear whether copper itself, accumulating in the liver and in the brain, is cytotoxic, or outcome after traumatic brain damage (Teasdale et al., 1997; Welsh-Bohmer et al., 1997) . The ApoE 2 protein appears whether peroxidation is caused by the interaction of copper and iron. However, it is known that ApoE is able to bind to protect patients against coronary arteriosclerosis (Siest et al., 1995) . metal ions, with the highest affinity for copper (Miyata and Smith, 1996) . Moreover, it has been suggested that the ApoE is a key protein for the transport of cholesterol esters and lipids in the CNS. In contrast to the brain where sequestering of copper might be the most important mechanism responsible for the antioxidative effect of the ApoE is the major apolipoprotein, the liver synthesizes a greater amount and several different apolipoproteins, resulting ApoE protein. In addition, it has been speculated that the affinity of ApoE proteins for copper and other metal ions in a comparatively low plasma concentration of ApoE. On the other hand, low density lipoprotein (LDL) receptor varies depending on the ApoE isoform (Miyata and Smith, 1996) . However, copper toxicity may not be restricted to expression and apolipoprotein synthesis (including ApoE
